{"protocolSection": {"identificationModule": {"nctId": "NCT01346852", "orgStudyIdInfo": {"id": "112607"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients", "officialTitle": "Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients"}, "statusModule": {"statusVerifiedDate": "2017-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-07"}, "primaryCompletionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-04-15", "studyFirstSubmitQcDate": "2011-05-02", "studyFirstPostDateStruct": {"date": "2011-05-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-05-05", "resultsFirstSubmitQcDate": "2011-05-05", "resultsFirstPostDateStruct": {"date": "2011-06-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-05-25", "lastUpdatePostDateStruct": {"date": "2017-05-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the predictive ability of three asthma risk markers: the ratio of controller medication to total asthma medication, an albuterol only marker, and an oral corticosteroid use marker, as well as to compare the precision of these tools between adult and pediatric patient populations. This retrospective longitudinal analysis will use 2 different databases: a large managed care database and a large fee for service Medicaid database."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["pediatrics", "Medicaid", "asthma", "outcomes", "asthma medication ratio"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 101437, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Pediatric participants", "description": "Pediatric participants (age 4 to 17) with a diagnosis of asthma", "interventionNames": ["Drug: Asthma treatment with an asthma-related medication and at least one asthma controller medication"]}, {"label": "Adult participants", "description": "Adult participants (age 18 and older) with a diagnosis of asthma", "interventionNames": ["Drug: Asthma treatment with an asthma-related medication and at least one asthma controller medication"]}], "interventions": [{"type": "DRUG", "name": "Asthma treatment with an asthma-related medication and at least one asthma controller medication", "description": "participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.", "armGroupLabels": ["Adult participants", "Pediatric participants"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Ratio of Controller Medication to Total Asthma Medication", "description": "The ratio of controller medication (CM) to total asthma medication (AM), which is well established in predicting future asthma events in adults, was calculated as the ratio of the units of CMs used during the defined period divided by the sum of the units of CMs plus the units of inhaled short-acting beta-agonists used during the same period. A CM is defined as any inhaled corticosteroid containing medication, methylxanthines, leukotriene receptor antagonists, or cromolyn sodium. The ratio is calculated using all CM. Asthma controllers are medications used to treat asthma on a regular basis.", "timeFrame": "January 1, 2004 to June 30, 2006: 3, 6, and 12 month follow-up periods"}], "secondaryOutcomes": [{"measure": "Mean Number of Short-acting Beta-agonist (SABA) Canisters Used", "description": "The number of albuterol canisters dispensed is a marker that is well established in predicting future asthma events in an adult population.", "timeFrame": "January 1, 2004 to June 30, 2006: 3, 6, and 12 month follow-up periods"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with asthma as determined by ICD-9 codes and asthma drug use\n* at least 4 years of age\n* use of at least 1 controller or at least 5 albuterol prescriptions in 12 months\n\nExclusion Criteria:\n\n* Subjects with COPD or treatment for COPD", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "The study intends to identify subjects at least 4 years of age with asthma and using asthma medications", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Pediatric Participants Diagnosed With Asthma", "description": "Pediatric (4-17 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known."}, {"id": "FG001", "title": "Adult Participants Diagnosed With Asthma", "description": "Adult (\\>=18 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "41753"}, {"groupId": "FG001", "numSubjects": "59684"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "41753"}, {"groupId": "FG001", "numSubjects": "59684"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Pediatric Participants Diagnosed With Asthma", "description": "Pediatric (4-17 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known."}, {"id": "BG001", "title": "Adult Participants Diagnosed With Asthma", "description": "Adult (\\>=18 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "41753"}, {"groupId": "BG001", "value": "59684"}, {"groupId": "BG002", "value": "101437"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.1", "spread": "4.0"}, {"groupId": "BG001", "value": "43.6", "spread": "13.3"}, {"groupId": "BG002", "value": "29.8", "spread": "19.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "18339"}, {"groupId": "BG001", "value": "38211"}, {"groupId": "BG002", "value": "56550"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23414"}, {"groupId": "BG001", "value": "21473"}, {"groupId": "BG002", "value": "44887"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Ratio of Controller Medication to Total Asthma Medication", "description": "The ratio of controller medication (CM) to total asthma medication (AM), which is well established in predicting future asthma events in adults, was calculated as the ratio of the units of CMs used during the defined period divided by the sum of the units of CMs plus the units of inhaled short-acting beta-agonists used during the same period. A CM is defined as any inhaled corticosteroid containing medication, methylxanthines, leukotriene receptor antagonists, or cromolyn sodium. The ratio is calculated using all CM. Asthma controllers are medications used to treat asthma on a regular basis.", "populationDescription": "Ingenix Impact National Managed Care Database members who had \\>=1 ICD-9 code for asthma and had \\>= 1 controller medication or \\>=5 albuterol canisters dispensed identified in the database during the 12-month identification period (pre-index). We tested 3 different capture/follow-up periods; thus, sample sizes varied depending capture period used.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "January 1, 2004 to June 30, 2006: 3, 6, and 12 month follow-up periods", "groups": [{"id": "OG000", "title": "Pediatric Participants Diagnosed With Asthma", "description": "Pediatric (4-17 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known."}, {"id": "OG001", "title": "Adult Participants Diagnosed With Asthma", "description": "Adult (\\>=18 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40659"}, {"groupId": "OG001", "value": "59174"}]}], "classes": [{"title": "3 months, n=40419, 59016", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.57", "spread": "0.34"}, {"groupId": "OG001", "value": "0.66", "spread": "0.34"}]}]}, {"title": "6 months, n=40525, 59091", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "0.26"}, {"groupId": "OG001", "value": "0.71", "spread": "0.29"}]}]}, {"title": "12 months, n=40659, 59174", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.63", "spread": "0.26"}, {"groupId": "OG001", "value": "0.70", "spread": "0.29"}]}]}]}, {"type": "SECONDARY", "title": "Mean Number of Short-acting Beta-agonist (SABA) Canisters Used", "description": "The number of albuterol canisters dispensed is a marker that is well established in predicting future asthma events in an adult population.", "populationDescription": "Ingenix Impact National Managed Care Database members who had \\>=1 ICD-9 code for asthma and had \\>= 1 controller medication or \\>=1 albuterol canister dispensed during the 12-month pre-index period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "canisters", "timeFrame": "January 1, 2004 to June 30, 2006: 3, 6, and 12 month follow-up periods", "groups": [{"id": "OG000", "title": "Pediatric Participants Diagnosed With Asthma", "description": "Pediatric (4-17 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known."}, {"id": "OG001", "title": "Adult Participants Diagnosed With Asthma", "description": "Adult (\\>=18 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41753"}, {"groupId": "OG001", "value": "59684"}]}], "classes": [{"title": "3 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.03", "spread": "0.90"}, {"groupId": "OG001", "value": "1.04", "spread": "1.06"}]}]}, {"title": "6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.24", "spread": "1.18"}, {"groupId": "OG001", "value": "1.28", "spread": "1.57"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.72", "spread": "1.86"}, {"groupId": "OG001", "value": "1.82", "spread": "2.71"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "This was a retrospective observational study using a large health insurance claims database. Serious adverse events and non-serious adverse events were not collected.", "eventGroups": [{"id": "EG000", "title": "Pediatric Participants Diagnosed With Asthma", "description": "Pediatric (4-17 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known.", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG001", "title": "Adult Participants Diagnosed With Asthma", "description": "Adult (\\>=18 years old) participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication during the enrollment period (January 1, 2004 to June 30, 2006) and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol. Due to the retrospective nature of this analysis, doses received and frequency of dosing are not known.", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M7386", "name": "Cromolyn Sodium", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}]}}, "hasResults": true}